AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (6.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets

Huanyu Zhao1Ruoyu Dang1Yipan Zhu1Baijian Qu1Yasra Sayyed1Ying Wen1Xicheng Liu2Jianping Lin1Luyuan Li1 ( )
State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
Show Author Information

Abstract

Objective

The aim of this study was to identify hub genes associated with immune cell infiltration in breast cancer through bioinformatic analyses of multiple datasets.

Methods

Nonparametric (NOISeq) and robust rank aggregation-ranked parametric (EdgeR) methods were used to assess robust differentially expressed genes across multiple datasets. Protein-protein interaction network, GO, KEGG enrichment, and sub-network analyses were performed to identify immune-associated hub genes in breast cancer. Immune cell infiltration was evaluated with the CIBERSORT, XCELL, and TIMER methods. The association between the hub gene-based risk signature and survival was determined through Kaplan–Meier survival analysis, multivariate Cox analysis, and a nomogram with external verification.

Results

We identified 163 robust differentially expressed genes in breast cancer through applying both nonparametric and parametric methods to multiple GEO (n = 2,212) and TCGA (n = 1,045) datasets. Integrated bioinformatic analyses further identified 10 hub genes: CXCL10, CXCL9, CXCL11, SPP1, POSTN, MMP9, DPT, COL1A1, ADAMDEC1, and RGS1. The 10 hub-gene-based risk signature significantly correlated with the prognosis of patients with breast cancer. Moreover, these hub genes were strongly associated with the extent of infiltration of CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and myeloid dendritic cells into breast tumors.

Conclusions

Integrated analyses of multiple databases led to the discovery of 10 robust hub genes that together may serve as a risk factor characteristic of the immune microenvironment in breast cancer.

Electronic Supplementary Material

Download File(s)
cbm-19-9-1352_ESM.pdf (3.8 MB)

References

1

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-49.

2

Harbeck N, Gnant M. Breast cancer. Lancet. 2017; 389: 1134-50.

3

Ren Z, Lv M, Yu Q, Bao J, Lou K, Li X. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression. FASEB J. 2021; 35: e21383.

4

Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011; 60: 319-26.

5

Tower H, Ruppert M, Britt K. The immune microenvironment of breast cancer progression. Cancers. 2019; 11: 1375.

6

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.

7

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012; 486: 346-52.

8

Xie Y, Davis Lynn BC, Moir N, Cameron DA, Figueroa JD, Sims AH. Breast cancer gene expression datasets do not reflect the disease at the population level. NPJ Breast Cancer. 2020; 6: 39.

9

Jin H, Huang X, Shao K, Li G, Wang J, Yang H, et al. Integrated bioinformatics analysis to identify 15 hub genes in breast cancer. Oncol Lett. 2019; 18: 1023-34.

10

Hao M, Liu W, Ding C, Peng X, Zhang Y, Chen H, et al. Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis. PeerJ. 2020; 8: e9946.

11

Clare SE, Shaw PL. “Big data” for breast cancer: Where to look and what you will find. NPJ Breast Cancer. 2016; 2: 16031.

12

Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28: 573-80.

13

Tarazona S, Furió-Tarí P, Turrà D, Pietro AD, Nueda MJ, Ferrer A, et al. Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. Nucleic Acids Res. 2015; 43: e140.

14

Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38: 675-8.

15

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498-504.

16

Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.

17

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12: 453-7.

18

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48: W509-14.

19

Guan X, Xu ZY, Chen R, Qin JJ, Cheng XD. Identification of an immune gene-associated prognostic signature and its association with a poor prognosis in gastric cancer patients. Front Oncol. 2020; 10: 629909.

20

Stupnikov A, McInerney CE, Savage KI, McIntosh SA, Emmert-Streib F, Kennedy R, et al. Robustness of differential gene expression analysis of RNA-seq. Comput Struct Biotechnol J. 2021; 19: 3470-81.

21

Wu D, Pan Y, Zheng X. Identification of hub genes-based predictive model in hepatocellular carcinoma by robust rank aggregation and regression analysis. J Cancer. 2021; 12: 1884-93.

22

Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018; 27: 233-44.

23

Haynes WA, Vallania F, Liu C, Bongen E, Tomczak A, Andres-Terrè M, et al. Empowering multi-cohort gene expression analysis to increase reproducibility. Pac Symp Biocomput. 2017; 22: 144-53.

24

Lofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, et al. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI insight. 2016; 1: e89073.

25

Sweeney TE, Haynes WA, Vallania F, Ioannidis JP, Khatri P. Methods to increase reproducibility in differential gene expression via meta-analysis. Nucleic Acids Res. 2017; 45: e1.

26

House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived cxcl9 and cxcl10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020; 26: 487-504.

27

Liang YK, Deng ZK, Chen MT, Qiu SQ, Xiao YS, Qi YZ, et al. CXCL9 is a potential biomarker of immune infiltration associated with favorable prognosis in er-negative breast cancer. Front Oncol. 2021; 11: 710286.

28

Chen L, Zeng T, Pan X, Zhang YH, Huang T, Cai YD. Identifying methylation pattern and genes associated with breast cancer subtypes. Int J Mol Sci. 2019; 20: 4269.

29

Pan X, Hu X, Zhang YH, Chen L, Zhu L, Wan S, et al. Identification of the copy number variant biomarkers for breast cancer subtypes. Mol Genet Genomics. 2019; 294: 95-110.

30

Schilder BM, Navarro E, Raj T. Multi-omic insights into parkinson‘s disease: from genetic associations to functional mechanisms. Neurobiol Dis. 2022; 163: 105580.

Cancer Biology & Medicine
Pages 1352-1374
Cite this article:
Zhao H, Dang R, Zhu Y, et al. Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets. Cancer Biology & Medicine, 2022, 19(9): 1352-1374. https://doi.org/10.20892/j.issn.2095-3941.2021.0586

179

Views

4

Downloads

5

Crossref

8

Web of Science

7

Scopus

Altmetrics

Received: 23 December 2021
Accepted: 25 February 2022
Published: 22 September 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return